Skip to main content
Platform for generating a seasonal vaccine for both influenza and coronaviruses

Platform for generating a seasonal vaccine for both influenza and coronaviruses

Unmet Need Similar to the flu vaccine, the need for seasonal post-immunization boosting to offer protection following COVID-19 vaccines remains possible. However, more than 8 percent of people who received a first dose of Pfizer…

Read More

Novel small molecule mast cell activator vaccine adjuvants

Novel small molecule mast cell activator vaccine adjuvants

Value Proposition Mast cells (MCs) are innate immune cells highly prevalent in the dermal region of the skin and in the respiratory, gastrointestinal, and urinary tract mucosa. The strategic location at the host–environment interface and…

Read More

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Value proposition Immunization with vaccines prevent illness, disability, and currently avert an estimated 2 to 3 million deaths every year. However, commonly-used vaccine technology platforms can be unpredictable, require a high manufacturing cost, and often…

Read More

Replication competent bi- and tri-valent influenza viruses as vaccines

Replication competent bi- and tri-valent influenza viruses as vaccines

Value Proposition Influenza infection is a major public health concern, with an estimated 200,000 Americans hospitalized each year with flu or flu-related illness. The most effective method for flu prevention is vaccination, however, due to…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us